Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 282 participants.
Also called NCT05186818
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 282 participants
- Registry
-
NCT05186818 -
2021-003536-92
-
- Other papers using this trial's data
- Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial
- Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial
- Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial
- Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants
- Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
- Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy
- Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
- Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
- Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, China, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05186818. Randomized; double masking; primary purpose treatment. Start 2022-02-01 (actual); primary completion 2023-11-10 (actual). Results posted on 2026-03-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
- Acronym
- SEQUOIA-HCM
- Condition
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Intervention (Drug)
- Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
- Intervention (Drug)
- Placebo to match aficamten
- Lead sponsor
- Cytokinetics
- Collaborator
- Corxel Pharmaceuticals
Record details
- Record id
cardio:ct-nct05186818- Content hash
45d8de95816943d08ade1e7b63bf087ba46e4bc3c1405b7967ef7562ca0c6456